{"id":363318,"date":"2023-11-30T03:00:00","date_gmt":"2023-11-30T08:00:00","guid":{"rendered":"https:\/\/platohealth.ai\/aml-cell-therapy-trials-to-watch-in-2024-targeting-gvhd\/"},"modified":"2023-11-30T04:55:24","modified_gmt":"2023-11-30T09:55:24","slug":"aml-cell-therapy-trials-to-watch-in-2024-targeting-gvhd","status":"publish","type":"post","link":"https:\/\/platohealth.ai\/aml-cell-therapy-trials-to-watch-in-2024-targeting-gvhd\/","title":{"rendered":"AML cell therapy trials to watch in 2024 targeting GvHD","gt_translate_keys":[{"key":"rendered","format":"text"}]},"content":{"rendered":"
\n

Share this article<\/p>\n

<\/span><\/p>\n<\/div>\n

<\/p>\n

<!–<\/p>\n

\n

–><\/p>\n

\n
\n
There are several cell therapy candidates coming to the end of Phase II\/III clinical trials which could change the landscape for patients. Image credit: Shutterstock \/ Yomal2233<\/figcaption><\/figure>\n<\/p><\/div>\n
<\/figure>\n

Patients with Acute Myeloid Leukemia (AML) can sit on waiting list for months on end for a donor. After the elation of getting the call that they have a match and receiving a transplant, the elation can quickly change when the cells are rejected due to graft versus host disease (GvHD) or contract an infection.<\/p>\n

GvHD is a systemic disorder that occurs when the graft\u2019s immune cells recognise the host as foreign and attack the recipient\u2019s body cells. Being able to reduce the occurrence of GvHD is an unmet need in AML and something which precision medicine could assist with.<\/p>\n

According to analysis published by GlobalData in September 2023<\/a>, a patient-based forecast places the market value for cell therapies in AML at $708 million in the 8MM (US, 5EU, Japan, and China) by 2032. GlobalData<\/a> is the parent company of Clinical Trials Arena.<\/em><\/p>\n

Cell therapies are used as supportive products after hematopoietic stem cell transplants (HSCT) that aim to either speed up haematopoietic recovery or prolong GvHD relapse-free survival.<\/p>\n

Gamida Cell\u2019s omidubicel<\/a>, marketed as NiCord, is the first cell therapy on the market for AML patients attempting to target GvHD recurrence. The product was given the nod by the US Food and Drug Administration (FDA) in April 2023. NiCord improves the efficacy of bone marrow transplant for hematologic malignancies.<\/p>\n

Dr Sandeep Nayak, from MACS Clinic in Bengaluru, India, says that the development of these cell therapies will improve patient outcomes if proved efficacious. \u201cPatients and families need to understand that while these developments are promising, they are still under investigation,\u201d Nayak says.<\/p>\n

\n

Access the most comprehensive Company Profiles
\n on the market, powered by GlobalData. Save hours of research. Gain competitive edge.<\/p>\n